Home > Insider Trading > Filing (0000899243-20-019863)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1807901	Pandion Therapeutics Inc.	PAND	Pharmaceutical Preparations (2834)	833015614

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1817449	Nancy Stagliano	C/O Pandion Therapeutics, Inc., 134 Coolidge Avenue Watertown MA 02472		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-21	15,004	$0.00	73,067	No	4	C	Indirect	By The Nancy E. Stagliano Trust
Common Stock	Acquisiton	2020-07-21	1,000	$18.00	1,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By The Nancy E. Stagliano Trust
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2020-07-17	3,674	$0.00	3,674	$18.00
Common Stock	Stock Option (right to buy)	Acquisiton	2020-07-17	13,997	$0.00	13,997	$18.00
Common Stock	Series A Preferred Stock	Disposition	2020-07-21	28,620	$0.00	5,612	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-21	47,898	$0.00	9,392	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,674	2030-07-16	No	4	A	Direct
13,997	2030-07-16	No	4	A	Direct
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.
This option award was granted on July 17, 2020. The shares underlying the award vest in equal quarterly installments following June 28, 2018 through June 28, 2022, subject to the reporting person's continued service on each applicable vesting date.
This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date.